Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-27
1996-04-09
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31445
Patent
active
055062415
ABSTRACT:
A method for preventing fibrin formation in anterior chamber characterized by administering argatroban into the anterior chamber is provided. A phermaceutical preparation for irrigation, eye drop, and drip infusion to effect the said method is also provided.
REFERENCES:
patent: 4117127 (1978-09-01), Okamoto et al.
patent: 4131673 (1978-12-01), Okamoto et al.
patent: 4201863 (1980-05-01), Okamoto et al.
patent: 5141947 (1992-08-01), Tamao et al.
Hijikata--Okunomiya et al. Thromb. Res. vol. 45 No. 5, 1987, pp. 699-702.
Schneider, Thromb. Res. vol. 64 No. 6, 1991, pp. 677-689.
Jaffe et al., Opthalmology vol. 97 No. 2, 1990, pp. 184-189.
Mano Tomiya
Shiomura Jin
Fay Zohreh
Mitsubishi Chemical Corporation
LandOfFree
Argatroban preparations for ophthalmic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Argatroban preparations for ophthalmic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Argatroban preparations for ophthalmic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139300